Objective-C-Reactive protein (CRP) is the prototype acute phase protein and a cardiovascular risk factor. Interleukin-1␤
protein in humans. 1 Although recently controversially discussed, numerous prospective epidemiological studies indicate that CRP is a powerful marker of future cardiovascular risk. [2] [3] [4] [5] In some studies, CRP plasma levels even better predict cardiovascular events than low-density lipoprotein cholesterol levels. 4 CRP may have direct proatherogenic properties. For example, the molecule is thought to activate the complement system in atherosclerotic lesions, 6, 7 stimulate endothelial cells, 8, 9 and smooth muscle cells. 10, 11 Furthermore, CRP may participate in foam cell formation. 12 Although few antiatherogenic effects of CRP have been reported, 13 the published evidence suggests a proatherogenic net effect. Importantly, human CRP transgene expression causes markedly accelerated aortic atherosclerosis in apolipoprotein E-deficient male mice, with a similar although not statistically significant trend in females, which provides first in vivo evidence for a direct role of CRP in atherogenesis. 14 Thus , inhibition of CRP synthesis may be a strategy to prevent cardiovascular disease. 15 CRP is primarily synthesized in hepatocytes. 1 Preliminary evidence suggests that CRP is also expressed in vascular cells and atherosclerotic lesions. 7, 16 The molecular mechanisms of CRP synthesis have only been partly unraveled because availability of primary human hepatocytes (PHHs) is severely limited 17 because of ethical and technical reasons, and the endogenous CRP gene in hepatoma cell lines is hardly active. It is known mainly from studies in hepatoma cell lines 18 -23 that CRP synthesis is stimulated by cytokines, especially interleukin-1␤ (IL-1␤) and IL-6. Transcription factors involved in IL-6 -mediated CRP synthesis include signal transducer and activator of transcription 3 (STAT3) and members of the C/EBP family, especially C/EBP␣, ␤, and ␦. Furthermore, the nuclear factor B (NF-B) subunits p50 and p65 are involved in cytokine induction of CRP synthesis. In various cells, NF-B activation involves upstream protein kinase C (PKC) activation, in particular PKC␤. 24 -26 The PKC family is an enzyme family, the members of which are allosterically activated by diacylglycerol. 27 Phorbol 12,13dibutyrate (PDBu), a synthetic member of the phorbol esters, strongly activates the conventional PKC pathway, resulting in phosphorylation of Ser 105 within the activation domain of C/EBP␤, enhancing its transcriptional activity. 28 Despite the importance of this signaling cascade, involvement of the PKC pathway in regulation of CRP expression has never been investigated.
Here we identify the PKC pathway as a novel pathway in the regulation of CRP expression. Furthermore, we show that stable transfection of hepatoma G2 (HepG2) cells with the 1-kb CRP promoter-luciferase construct provides a reporter cell line strongly inducible by IL-1␤, IL-6, or PDBu. This cell line may be useful for high throughput screening (HTS) to identify inhibitors of CRP synthesis in hepatocytes for the prevention of cardiovascular disease.
Materials and Methods

Cell Culture
Human hepatoma cell line HepG2 (DSMZ) was grown in Iscove's medium (GIBCO) supplemented with 10% FCS and 1% penicillin/ streptomycin (GIBCO). PHHs were obtained from Cytonet GmbH, aortic smooth muscle cells (AoSMCs) from PromoCell GmbH, and human umbilical vein endothelial cells (HUVECs) from Clonetics.
Stable Transfection of HepG2 Cells With p1000CRP/Luciferase
A fragment of human CRP promoter (Ϫ1005 to ϩ12 bp) was cloned from human genomic DNA. Forward primer: 5Ј-ATGGTACCGTA-AGATTGACAGACAGTGTGGAG-3Ј; reverse primer: 5Ј-ATCTC-GAGGGCTAGAAGTCCTAGATCTCTTGC-3Ј. The polymerase chain reaction (PCR) fragment was digested with Kpn-XhoI restriction enzymes, cloned into pGL3-BasicVector (Promega) and sequenced. Cells were cotransfected with the p1000/CRP/luciferase construct and pcDNA 3.1 using Lipofectamine 2000 (LF2000; Invitrogen). Standard medium containing 1 mg/mL G418 (Invitrogen) was added. Clones were isolated after 18 days; 1 of the clones (HepG2-ABEK14) with IL-6 -inducible p1000/CRP/luciferase reporter activity was used for further experiments. Batch to batch differences were tested with a second stably transfected cell line.
Transient Transfection of HepG2 Cells With NF-B-Luciferase
Transfection was performed using LF2000 (Invitrogen). Cells were incubated with the transfection mixture (0.1 g of reporter plasmid DNA and 2.5 L of LF2000 in 500 L medium) for 5 hours. Transfection efficiency was Ϸ20% to 30% as assessed by green fluorescent protein-expressing plasmid (pEGFP; Clontech). One day after transfection, cells were treated with the cytokines or PDBu. Bright-Glo Luciferase Assays (Promega) were performed and measured by luminometer (Lumistar). Data were normalized to total protein.
Inhibitors
Stock solutions were prepared in DMSO (10 mmol/L). Cells were pretreated with inhibitors (final DMSO concentration 0.2%) for 1 hour before stimulation with cytokines or PDBu. Control cells were treated with identical media, including DMSO without cytokines. IB kinase complex inhibitor I229 inhibits the IB kinase complex (IKK␣ and IKK␤) with an in vitro IC 50 ϭ3.0 nmol/L. 29 Specificity of I229 against 14 different serine/threonine and tyrosine kinases (percent inhibition at 10 mol/L and 5.0 mol/L ATP [in vitro kinase reaction]) is summarized in the Table (nϭ5). The bisindolylmaleimide derivative LY333531 (Calbiochem) inhibits the PKC␤I (in vitro IC 50 ϭ4.7 nmol/L) and PKC␤II (IC 50 ϭ5.9 nmol/L) isozymes 30, 31 60-to 70-fold more selectively than PKC␣ and other PKC isoforms. 31
Quantitative Real-Time PCR
Total RNA was isolated from PHHs, HUVECs, and AoSMCs using RNeasy Kit (Qiagen). Purity was assessed using capillary electrophoresis Caliper Laboratory Chip system (Agilent 2100 Bioanalyser). Real-time quantitative PCR was performed using QuantiTect SYBR-Green Probe RT-PCR Kit (Qiagen). Each sample was assayed in triplicate. For relative quantification, the ⌬C t method (ratioϭ2 Ϫ[⌬Ct(CRP)Ϫ⌬Ct(GAPDH)] ) was used with GAPDH as a control. For copy number determination, a calibration curve was obtained using serial dilutions of a linearized GAPDH cDNA with the GAPDH primer pair forward: 5Ј-GAAGGTGAAGGTCGGAGTC-3Ј and reverse: 5Ј-GAAGATGGTGATGGGATTTC-3Ј as a template. Statistical analysis of RT-PCR data were performed using Q-gene software. Human CRP primer pair 1 (product size 133 bp): forward 5Ј-ACTTCCTATGTATCCCTCAAAG-3Ј; reverse: 5Ј-CTCATTG-TCTTGTCTCTTGGT-3Ј. Human CRP primer pair 2 (product size 440 bp): forward 5Ј-TCGTATGCCACCAAGAGAAGACA-3Ј; reverse: 5Ј-AACACTTCGCCTTGCACTTCATACT-3Ј. 16 Primer pair 3 was designed to distinguish between mRNA and genomic DNA because forward and reverse primers are specific for the different CRP exons (expected product size 196 bp for mRNA and 481 bp for genomic DNA): forward 5Ј-TCTCATGCTTTTGGCCAGAC-3Ј; reverse: 5Ј-CTCATTGTCTTGTCTCTTGGT-3Ј.
End Point PCR Product Analysis
Quality and size of PCR end point product were determined using capillary electrophoresis Caliper Laboratory Chip system (Agilent 2100 Bioanalyser).
Immunostaining
HepG2 cells were fixed in 4% formaldehyde and permeabilized with 0.5% Triton X-100 (Sigma). Nonspecific binding was blocked with Super Block (Pierce). Cells were stained with polyclonal rabbit anti-PKC␤II (Santa Cruz Biotechnology) and goat anti-rabbit IgG (Alexa Fluor 594). Microscopy and photoimaging were assessed with Nikon Eclipse TE300 microscope (ϫ60).
CRP ELISA
Concentration of CRP in the supernatant of PHHs and other cells was measured by CRP-ELISA (IMUCLONE CRP (high sensitivity)
ELISA; American Diagnostica) according to manufacturer recommendations. Samples were diluted 1:10 and measured in triplicates. Experiments were repeated 3ϫ and statistical analysis performed as indicated below.
Statistical Analysis
Statistical analysis was performed using SigmaStat version 2.0 software. Results are presented as meanϮSD. Tests included 1-way ANOVA, Tukey Test, and Student t test. A PϽ0.05 was considered statistically significant (*). A PϽ0.001 was considered highly significant (**).
Results
PDBu Induces CRP Transcription and Protein Synthesis in PHHs
PHHs were treated with IL-1␤, IL-6 (10 ng/mL), and PDBu (100 nmol/L; Figure 1 ). CRP mRNA was measured by
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Abl CKII  CAMII  CDK1  CDK2  EGFR  ERK42  PKA  PKCa  P38  GSK3b  IRK  MEK1  Src  IKK   % inhibition at 10 mol/L  12  0  35  0  18  0  5  25  7  26  0  32  3  34  100 quantitative RT-PCR ( Figure 1A ), whereas CRP release was assessed by ELISA from cell supernatants ( Figure 1B ). The figure shows that PDBu significantly stimulates CRP transcription by 21.0Ϯ9.24-fold and protein release by 2.9Ϯ0.5-fold.
PDBu Stimulates CRP Promoter Activity in HepG2-ABEK14 Cells
In search for an appropriate cell culture model to study CRP synthesis in high throughput applications, HepG2 cells were stably transfected with p1000CRP/luciferase. The clones were treated with IL-1␤, IL-6, and PDBu, and 1 of the clones (HepG2-ABEK14) was chosen for further analyses. Whereas IL-1␤ and IL-6 increased promoter activity up to 5-fold only, synergistic activation was seen for IL-1␤/IL-6 (10 ng/mL each) with a 28-fold increase (Figure 2A ), which is particular for this cell line compared with PHHs (42.66Ϯ15.08-fold induction for combined IL-1␤/IL-6 treatment after 24 hours; Figure 1A ). Treatment with PDBu stimulated the CRP reporter by 5.39Ϯ0.66-fold and thus at least to the same extent as treatment with IL-1␤ or IL-6 ( Figure 2B ). Triple treatment with IL-1␤/IL-6/PDBu (100 nmol/L) induced a very strong activation (Ͼ100-fold), which is particular for this cell line compared with PHHs (13.33Ϯ3.77-fold induction for combined IL-1␤/IL-6/PDBu treatment after 24 hours; Figure  1A ). Dose dependency of PDBu-mediated superinduction showed an apparent plateau at 100 nmol/L PDBu ( Figure  2C ). Therefore, PDBu was used at 100 nmol/L in our experiments. To exclude positional effects on the activity of the CRP promoter in our cell line, batch to batch differences were tested with a second stably transfected cell line. Responsiveness to cytokine or PDBu stimulation was essentially the same. As expected, no detectable CRP synthesis (see Figure 5 ) or secretion (data not shown) was detected for HepG2 cells, and no detectable CRP secretion was found in HepG2-ABEK14 cells (data not shown). 
PDBu Activates PKC␤II in HepG2-ABEK14 Cells
To confirm that phorbol ester treatment indeed engages PKC, PKC␤II translocation was measured on PDBu treatment in HepG2 cells. PKC␤II indeed translocated to the nuclear membrane 60 minutes after stimulation with PDBu (100 nmol/L; Figure 5A ). During longer treatment (24 hours), we observed a marked decrease of PKC protein content, which is common phenomenon related to PKC activation. LY333531 dose-dependently inhibited CRP promoter activation by PDBu. However, IL-1␤/IL-6 -mediated activation was not inhibited by LY333531, indicating independency of the pathways ( Figure 5B ) in HepG2-ABEK14 cells.
PKC-Mediated Transcriptional Regulation of CRP Promoter Is NF-B Dependent
IKK inhibitor I229 abolished stimulatory effects of IL-1␤/ IL-6 and PDBu on regulation of the CRP reporter ( Figure  3B ), indicating NF-B involvement in regulation of the CRP promoter. This was further supported by NF-B reporter analyses in HepG2 cells transiently transfected with NF-Bluciferase reporter ( Figure 3C ). IL-1␤ and PDBu induced IKK and, subsequently, NF-B activation. IL-1␤ and PDBu induced NF-B-luciferase reporter equally strong, whereas IL-6 had no effect ( Figure 3C ). Inhibition of the IKK complex with I229 completely blocked the effect of IL-1␤ and partially the effect of PDBu. In analogy to the observation on CRP promoter activation ( Figure 3B ), LY333531 dosedependently inhibited the effects of PDBu on NF-B promoter, whereas IL-1␤/IL-6 -mediated activation was not inhibited by LY333531. Competition experiments with LY333531 revealed that PDBu-induced NF-B activation is totally PKC dependent but only partially IKK dependent, thus indicating potential involvement of additional kinases in PKC-mediated NF-B stimulation. Neither LY333531 nor I229 had an effect on basal luciferase activity on its own (data not shown).
IL-8 PKC-Dependently Induces CRP Protein Release in PHHs
In search for a physiological PKC activator, PHHs were treated with IL-8 (10 ng/mL). CRP concentration in cell supernatants was measured by ELISA. IL-8 significantly induced CRP protein release by 58.675Ϯ19.1-fold, and release was highly significantly reduced by LY333531 treatment down to 12.36Ϯ5.39-fold. Toxic effects were excluded by measurement of lactat dehydrogenase release (Figure 4 ).
Regulation of CRP Promoter in Other Cell Types
To investigate whether the stimulatory effect of PDBu is restricted to PHHs and HepG2-ABEK14 cells, we also tested AoSMCs and HUVECs. Cells were treated with IL-1␤, IL-6, or PDBu ( Figure 5A through 5C ). In PHHs, CRP mRNA levels measured by quantitative RT-PCR showed, as expected, a strong regulation of CRP mRNA after IL-6 stimulation and a weaker although still highly significant regulation after IL-1␤ and PDBu treatment. However, in contrast to HepG2-ABEK14 cells, no synergistic enhancement was observed for either double treatment with IL-1␤ and IL-6 nor for triple treatment with IL-1␤, IL-6, and PDBu in PHHs (Figure 1 ). This may be because of the fact that in PHHs, IL-6 alone elicits maximum possible stimulation or that PDBu induces IL-6 receptor shedding in some cells. 32 In AoSMCs and HUVECs, no significant regulation of CRP mRNA was observed for IL-1␤, IL-6, or PDBu treatment. Assessment of copy numbers per 1000 nontreated cells showed that CRP expression in PHHs is several orders of magnitude higher than CRP expression in vascular cells. Furthermore, we were not able to detect any CRP release from AoSMCs and HUVECs by ELISA (data not shown).
Discussion
In addition to its role in innate immunity, CRP is an important cardiovascular risk factor and may well be a target for cardiovascular therapy. Three strategies are feasible: (1) inhibition of CRPmediated complement activation; (2) blockage of CRP receptors; and (3) inhibition of CRP synthesis. 1, 33, 34 The third of these strategies seems to be the most appropriate because the proatherogenic effects of CRP obviously involve Ͼ1 mechanism. To address this goal, an appropriate cellular model with well-defined signaling pathways controlling CRP expression is absolutely required.
Whereas IL-1␤ and IL-6 (signaling via the Janus kinase/ STAT pathway, C/EBP, and NF-B) are considered the major mediators of CRP synthesis, other pathways are poorly investigated. The PKC pathway identified in this report may be of potential importance for CRP regulation in vivo because stimulation of some receptor subclasses (eg, the receptors for thrombin or IL-8) induce PKC activation. 27, 35, 36 Thrombin, IL-8, and angiotensin II are possible in vivo candidates for PKC-mediated CRP induction. Their receptors are present on hepatocytes, 35, 36 and they are generated during sepsis and inflammatory diseases, in parallel with elevated CRP plasma levels. IL-8 has also been shown to be intimately associated with atherosclerosis. 37 Importantly, activation of PKC is known to result in the phosphorylation of Ser 105 within the activation domain of C/EBP␤, thereby enhancing its transcriptional activity. This may provide a transcriptional link explaining the effect of CRP induction via PDBu. 28 Thus, the major result of this report is the first description of an involvement of the PKC pathway in CRP gene expression. The latter is true for 2 hepatocytic cell types: PHHs and HepG2-ABEK14 cells.
A further investigation in HepG2-ABEK14 cells revealed that NF-B activation is involved in PKC-mediated transcriptional regulation of CRP synthesis. This is in line with observations from other cells, in which NF-B activation involves upstream PKC activation. 24 -26 In HepG2 cells transiently transfected with the NF-B reporter, PDBu and IL-1␤ induced NF-B equally strong. Competition experiments with LY333531 revealed that PDBu-induced NF-B activation is totally PKC dependent, whereas PDBu-induced NF-B activation is only partially blocked by the IKK inhibitors, indicating potential involvement of additional signal transducers. As expected, IL-1␤/IL-6 -mediated induction of CRP also involves NF-B, but this is a PKCindependent process. Altogether, these data show that effects of PKC activation on CRP promoter are partially mediated by NF-B on the 1 hand and another unknown mechanism on the other hand (eg, PKC-dependent activation of C/EBP as described previously by Trautwein et al). 28 It is intriguing to speculate that activation of G-protein-coupled receptors (eg, the IL-8 receptor or angiotensin II receptor) known to stimulate phospholipase C␤ and diacylglycerole production and, subsequently, PKC activation may induce CRP expression through NF-B and C/EBP transcription factors.
Whereas in PHHs, activation of the PKC pathway by PDBu results in induction of CRP on the transcriptional and protein level, there is no detectable protein induction by PDBu in HepG2-ABEK14 cells. The latter is not surprising because endogenous CRP synthesis in HepG2 cells is known not to be intact. However, hepatoma cell lines, and in particular HepG2 cells, display some major experimental advantages: (1) They are widely available and very easy to grow over several months; (2) In contrast to other hepatoma cell lines (eg, Hep3B cells), they do not require S2 conditions because they are hepatitis negative; and (3) Stable transfection of these cells with the 1-kb CRP promoter coupled to luciferase results in a cell line (HepG2-ABEK14) that responds to IL-1␤ and IL-6 (and PDBu). The cell line is stable, very easy to grow, and provides a simple readout (luciferase). Developing an effective transcriptional inhibitor of CRP synthesis for the prevention of cardiovascular disease is a multistep approach: (1) HTS with a cell culture model (relevant cells of hepatic origin, cheap, easy to culture over several months, simple readout); and (2) testing the "hits" in other models (ie, Hep3B, PHHs).
It is currently impossible to use PHHs for such HTS because they do not proliferate in culture, and to screen a drug library including hundreds of thousands of substances, billions of cells are required that need to be cultured over several weeks. Species differences in CRP biology argue against use of primary hepatocytes from other species. Therefore, as a side product of this study, the generation of HepG2-ABEK14 cells provides a cell line suitable for HTS to identify inhibitors of CRP synthesis.
To understand whether PKC-dependent CRP regulation is also critical in smooth muscle and endothelial cells, we performed analogous experiments with AoSMCs and HUVECs. We observed that IL-1␤ and PDBu potently stimulate CRP mRNA expression and protein release in PHHs, although much weaker than IL-6 does. In AoSMCs and HUVECs, we detected extremely low amounts of CRP mRNA, and we did not observe any significant regulation in response to IL-1␤, IL-6, or PDBu. No detectable CRP protein secretion has been found as well. Thus, either CRP synthesis in these cells is not relevant, or the endogenous CRP promoter is controlled by other cell-specific factors. Although there is some evidence that CRP may be produced by inflamed kidneys, 38 it is most likely that CRP, like many other genes, is mainly expressed in a tissuedependent manner (ie, is a preferentially liver-specific gene). 39 In this context, it is interesting to note that our CRP reporter construct showed no IL-1␤-or IL-6 -dependent regulation in renal human embryonic kidney 293 cells (data not shown).
In summary, our report demonstrates: (1) the PKC pathway as a novel pathway of CRP synthesis; (2) NF-B dependency of this pathway; (3) potential usefulness of HepG2-ABEK14 cells for HTS to identify transcriptional inhibitors of CRP synthesis; and (4) liver specificity of PKC-mediated CRP transcription.
